UNC Lineberger Comprehensive Cancer Center
University of North Carolina
Chapel Hill, NC
Accepting patients
QUINTESSENTIAL
Phase 2 Study of BMS-986393, a GPRC5D-directed CART-Cell Therapy, in Participants with Relapsed or Refractory Multiple Myeloma
- CAR T Cell
- GPRC5D
- Phase 2
Accepting patients
CERVINO
A Phase 3, Multicenter, Randomized, Open Label Study of Etentamig Compared With Standard Available Therapies in Subjects With Relapsed or Refractory Multiple Myeloma (3L+ RRMM Monotherapy Study)
- Bispecific Antibody
- BCMA
- Randomization
- Phase 3
Accepting patients
Etentamig (ABBV-383)
A Phase 1/2, Open-Label, Platform Study to Evaluate Safety and Efficacy of Etentamig Monotherapy or Etentamig Combinations in Subjects With Multiple Myeloma
- Bispecific Antibody
- BCMA
- Phase 1/2
Accepting patients
Etentamig for Newly Diagnosed Patients
Phase 2/3, Multicenter, Randomized, Open-Label Study Evaluating the Efficacy and Safety of Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Subjects With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant
- Bispecific Antibody
- BCMA
- CD3
- Randomization
- Phase 2/3
Accepting patients
Etentamig
A Study to Assess Adverse Events of Intravenously (IV) Infused Etentamig (ABBV-383) in Adult Participants With Relapsed or Refractory Multiple Myeloma
- Bispecific Antibody
- BCMA
- Phase 1
- Has results
Accepting patients
DREAMM-20
A Phase 1/2 Open-label, Multicentre, Dose Escalation and Expansion Study to Investigate the Safety, Tolerability, and Clinical Activity of Belantamab as Monotherapy and in Combination With Other Treatments in Participants With Multiple Myeloma
- Antibody Drug Conjugate (ADC)
- BCMA
- Phase 1/2
- Has results
Accepting patients
Isatuximab in Frail Patients
Isatuximab Plus Lenalidomide and Dexamethasone for Frail and/or Much Older Patients With Newly Diagnosed Multiple Myeloma
- Monoclonal Antibody
- CD38
- Phase 2
Accepting patients
TRIgnite-1
A Phase 1, First-in-Human, Multicenter, Open-Label, Dose Escalation and Dose-Expansion Study of Single-Agent ISB 2001 in Subjects With Relapsed/Refractory Multiple Myeloma
- T Cell
- Trispecific Antibody
- BCMA
- CD38
- Phase 1
- Has results
Accepting patients
Tissue, Blood, and Body Fluid Sample Collection
Tissue Procurement For Hematolymphoid Conditions
- Observational Trial
Accepting patients
Surzetoclax (ABBV-453)
A Phase 1/2, Open-Label, Platform Study to Evaluate Safety and Efficacy of the BCL-2 Inhibitor Surzetoclax (ABBV-453) Given as Monotherapy or in Combination With Antimyeloma Regimens in Subjects With Multiple Myeloma
- BCL-2 Inhibitor
- Phase 1/2
1 hidden based on your filters.Show All